ChengDu ShengNuo Biotec Co.,Ltd.

Shanghai Stock Exchange 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd. Receivables for the year ending December 31, 2023: USD 16.32 M

ChengDu ShengNuo Biotec Co.,Ltd. Receivables is USD 16.32 M for the year ending December 31, 2023, a -5.47% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

ChengDu ShengNuo Biotec Co.,Ltd. Receivables for the year ending December 31, 2022 was USD 17.27 M, a -1.80% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Receivables for the year ending December 31, 2021 was USD 17.58 M, a 8.20% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Receivables for the year ending December 31, 2020 was USD 16.25 M, a 13.69% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Receivables for the year ending December 31, 2019 was USD 14.29 M, a 41.87% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd.

CEO	Mr. Yongjun Wen
IPO Date	June 3, 2021
Location	China
Headquarters	258 Industrial Avenue Section
Employees	1,128
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Key trends

Past 5 years